044480.Kq
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
At a glance
News & coverage
3Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-06-25 · SE
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.62, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.9, suggesting limited short-term liquidity cushion. The company's price-to-book ratio is 4.61, and its price-to-tangible-book ratio is also 4.61, reflecting a premium valuation relative to its book value. However, the company's negative net income of -7,133,786,860 KRW and negative operating income of -1,931,629,150 KRW indicate a challenging earnings environment.
Profitability metrics show a return on equity of -0.291 and a return on assets of -0.1465, both significantly below zero, which is a clear sign of unprofitability. The company's gross profit of 5,114,262,620 KRW is modest compared to its revenue of 25,309,657,430 KRW, indicating a low gross margin. The operating cash flow of 721,547,130 KRW is positive but insufficient to cover the negative net income, highlighting operational inefficiencies.
The company's revenue is not segmented by geographic regions or product lines in the available data, making it difficult to assess geographic or segment concentration. However, the lack of detailed segment reporting suggests a potential concentration risk, as the company's performance is not diversified across multiple markets or product categories.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The negative net income and operating income suggest a lack of growth momentum. The company's free cash flow is negative at -6,416,300,730 KRW, indicating that it is not generating sufficient cash from operations to fund its capital expenditures and other operational needs.
The company's risk profile includes a medium liquidity risk, as indicated by the current ratio of 0.9. The risk assessment also notes that net cash is negative after subtracting total debt, which could pose a challenge in meeting short-term obligations. The dilution risk is assessed as low, and there are no immediate signs of dilution pressure from recent issuance or shelf registration.
Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The most recent analyst estimate for EPS is -1,491.74 KRW, reflecting a continued negative earnings trend. The absence of detailed recent events or transcripts limits the ability to assess the company's near-term strategic direction.
- The company is currently unprofitable, with a negative net income and operating income.
- The company's liquidity position is weak, with a current ratio of 0.9 and a negative net cash position after debt.
- The company's valuation is premium, as indicated by a price-to-book ratio of 4.61, but this is not supported by positive earnings.
- The company's growth trajectory is unclear, with no specific revenue growth projections provided.
- The company's risk profile includes medium liquidity risk and low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Forward curve
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 044480.KQ Market data — financials · 2026-05-26
- Billions Co Ltd Market data — analyst estimates · 2026-05-26
Ownership & reference
Leadership
- Seong Hun KimPresident, Chief Executive Officer, Director